These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 25257201

  • 1. 5-(4-((4-[(18)F]Fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine: a selective dual inhibitor for potential PET imaging of Trk/CSF-1R.
    Bernard-Gauthier V, Schirrmacher R.
    Bioorg Med Chem Lett; 2014 Oct 15; 24(20):4784-90. PubMed ID: 25257201
    [Abstract] [Full Text] [Related]

  • 2. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development.
    Bernard-Gauthier V, Mahringer A, Vesnaver M, Fricker G, Schirrmacher R.
    Bioorg Med Chem Lett; 2017 Jun 15; 27(12):2771-2775. PubMed ID: 28476569
    [Abstract] [Full Text] [Related]

  • 3. Efficient radiosynthesis and preclinical evaluation of [18 F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging.
    Singleton TA, Bdair H, Bailey JJ, Choi S, Aliaga A, Rosa-Neto P, Schirrmacher R, Bernard-Gauthier V, Kostikov A.
    J Labelled Comp Radiopharm; 2020 Mar 15; 63(3):144-150. PubMed ID: 31919878
    [Abstract] [Full Text] [Related]

  • 4. Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents.
    Bernard-Gauthier V, Aliaga A, Aliaga A, Boudjemeline M, Hopewell R, Kostikov A, Rosa-Neto P, Thiel A, Schirrmacher R.
    ACS Chem Neurosci; 2015 Feb 18; 6(2):260-76. PubMed ID: 25350780
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
    Li P, Cai S, Zhao T, Xu L, Guan D, Li J, Zhou J, Zhang H.
    Bioorg Med Chem Lett; 2021 Dec 01; 53():128409. PubMed ID: 34628036
    [Abstract] [Full Text] [Related]

  • 6. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats.
    Conway JG, Pink H, Bergquist ML, Han B, Depee S, Tadepalli S, Lin P, Crumrine RC, Binz J, Clark RL, Selph JL, Stimpson SA, Hutchins JT, Chamberlain SD, Brodie TA.
    J Pharmacol Exp Ther; 2008 Jul 01; 326(1):41-50. PubMed ID: 18434589
    [Abstract] [Full Text] [Related]

  • 7. Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors-Synthetic Strategies and SAR Insights.
    Mahajan AT, Shivani, Datusalia AK, Coluccini C, Coghi P, Chaudhary S.
    Molecules; 2024 Jul 29; 29(15):. PubMed ID: 39124968
    [Abstract] [Full Text] [Related]

  • 8. First-in-Human Brain Imaging of [18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.
    Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy JP, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR, Wängler C, Wängler B, Bartenstein P, Bernard-Gauthier V, Schirrmacher R.
    ACS Chem Neurosci; 2019 Jun 19; 10(6):2697-2702. PubMed ID: 31017386
    [Abstract] [Full Text] [Related]

  • 9. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.
    Pan S, Zhang L, Luo X, Nan J, Yang W, Bin H, Li Y, Huang Q, Wang T, Pan Z, Mu B, Wang F, Tian C, Liu Y, Li L, Yang S.
    J Med Chem; 2022 Feb 10; 65(3):2035-2058. PubMed ID: 35080890
    [Abstract] [Full Text] [Related]

  • 10. A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human.
    Bernard-Gauthier V, Bailey JJ, Mossine AV, Lindner S, Vomacka L, Aliaga A, Shao X, Quesada CA, Sherman P, Mahringer A, Kostikov A, Grand'Maison M, Rosa-Neto P, Soucy JP, Thiel A, Kaplan DR, Fricker G, Wängler B, Bartenstein P, Schirrmacher R, Scott PJH.
    J Med Chem; 2017 Aug 24; 60(16):6897-6910. PubMed ID: 28696690
    [Abstract] [Full Text] [Related]

  • 11. Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.
    Mamat C, Mosch B, Neuber C, Köckerling M, Bergmann R, Pietzsch J.
    ChemMedChem; 2012 Nov 24; 7(11):1991-2003. PubMed ID: 23042640
    [Abstract] [Full Text] [Related]

  • 12. Trk kinase inhibitors as new treatments for cancer and pain.
    Wang T, Yu D, Lamb ML.
    Expert Opin Ther Pat; 2009 Mar 24; 19(3):305-19. PubMed ID: 19441906
    [Abstract] [Full Text] [Related]

  • 13. Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: radiosynthesis and evaluation of 2-(4-[(18)F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-([N-methyl-(11)C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one.
    Bernard-Gauthier V, Boudjemeline M, Rosa-Neto P, Thiel A, Schirrmacher R.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7816-29. PubMed ID: 24183588
    [Abstract] [Full Text] [Related]

  • 14. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
    Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1543-7. PubMed ID: 20137931
    [Abstract] [Full Text] [Related]

  • 15. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
    Chen L, Chen Y, Zhang C, Jiao B, Liang S, Tan Q, Chai H, Yu W, Qian Y, Yang H, Yao W, Yu J, Luo Y, Plewe M, Wang J, Han XR, Liu J.
    J Med Chem; 2020 Dec 10; 63(23):14562-14575. PubMed ID: 33058680
    [Abstract] [Full Text] [Related]

  • 16. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Kitagawa D, Gouda M, Kirii Y, Sugiyama N, Ishihama Y, Fujii I, Narumi Y, Akita K, Yokota K.
    J Biochem; 2012 Jan 10; 151(1):47-55. PubMed ID: 21880693
    [Abstract] [Full Text] [Related]

  • 17. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
    Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V.
    Expert Opin Ther Pat; 2017 Jun 10; 27(6):733-751. PubMed ID: 28270010
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors.
    Kim YY, Choi J, Choi K, Park C, Kim YH, Suh KH, Ham YJ, Jang SY, Lee KH, Hwang KW.
    Bioorg Med Chem Lett; 2019 Jan 15; 29(2):271-275. PubMed ID: 30522957
    [Abstract] [Full Text] [Related]

  • 19. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
    Ross TL, Honer M, Lam PY, Mindt TL, Groehn V, Schibli R, Schubiger PA, Ametamey SM.
    Bioconjug Chem; 2008 Dec 15; 19(12):2462-70. PubMed ID: 19053298
    [Abstract] [Full Text] [Related]

  • 20. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
    Scott DA, Dakin LA, Del Valle DJ, Diebold RB, Drew L, Gero TW, Ogoe CA, Omer CA, Repik G, Thakur K, Ye Q, Zheng X.
    Bioorg Med Chem Lett; 2011 Mar 01; 21(5):1382-4. PubMed ID: 21295474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.